Clinical Trial Update: Roflumilast Safety Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily [Phase 4]

View source ↗

Summary

Phase 4 study evaluating safety of roflumilast when given once daily on alternate days for two weeks compared with the standard daily dose in chronic obstructiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: Fundación Pública Andaluza Progreso y Salud | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Status: COMPLETED